antibody-drug conjugate RC118
Term · Oncology and biomedicine · MLC-T-ONC-010181
An antibody-drug conjugate (ADC) composed of an as of yet undisclosed monoclonal antibody against a tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of ADC RC118 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.
| Identifier | MLC-T-ONC-010181 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | ADC RC118 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-010181",
"term": "antibody-drug conjugate RC118",
"field": "Oncology and biomedicine",
"definition": "An antibody-drug conjugate (ADC) composed of an as of yet undisclosed monoclonal antibody against a tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of ADC RC118 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.",
"synonyms": [
"ADC RC118"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/antibody-drug-conjugate-rc118/"
}
Record 1,261 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.